MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Dyax Corp. Company Profile (NASDAQ:DYAX)

Consensus Ratings for Dyax Corp. (NASDAQ:DYAX) (?)
Ratings Breakdown: 4 Hold Rating(s), 1 Buy Rating(s)
Consensus Rating:Hold (Score: 2.20)
Consensus Price Target: $37.00 (3.67% downside)

Analysts' Ratings History for Dyax Corp. (NASDAQ:DYAX)
Show:
DateFirmActionRatingPrice TargetActions
12/7/2015RBC CapitalReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/9/2015Leerink SwannDowngradeOutperform -> Market Perform$37.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/5/2015Needham & Company LLCDowngradeBuy -> HoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/2/2015Jefferies GroupDowngradeBuy -> Hold$37.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/2/2015WedbushDowngradeOutperform -> NeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/11/2015OppenheimerDowngradeOutperform -> Market Perform$26.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/1/2015Bank of AmericaBoost Price TargetBuy$16.00 -> $30.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/1/2014 forward)
Earnings History for Dyax Corp. (NASDAQ:DYAX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
2/22/2016        
10/28/2015Q315($0.08)($0.08)$24.96 million$24.70 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/29/2015Q215($0.04)($0.06)$23.40 million$264.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/29/2015Q115($0.05)($0.05)$21.79 million$20.40 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/24/2015Q414($0.04)($0.02)$19.90 million$26.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/28/2014Q314($0.06)($0.01)$15.70 million$22.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/29/2014Q214($0.05)($0.02)$14.13 million$19.59 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/30/2014($0.05)($0.05)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/28/2014Q413($0.04)($0.02)$15.84 million$16.90 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/22/2013Q313($0.05)($0.06)$14.80 million$13.70 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Dyax Corp. (NASDAQ:DYAX)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.04)($0.04)($0.04)
Q2 20161($0.04)($0.04)($0.04)
Q3 20161($0.03)($0.03)($0.03)
Q4 20162($0.01)$0.01$0.00
(Data provided by Zacks Investment Research)
Dividend History for Dyax Corp. (NASDAQ:DYAX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Dyax Corp. (NASDAQ:DYAX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
9/10/2015Thomas L KempnerDirectorSell6,000$22.47$134,820.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/28/2015Thomas L KempnerDirectorSell17,947$23.83$427,677.01View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/18/2015Thomas L KempnerDirectorSell18,035$23.83$429,774.05View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/13/2015Thomas L KempnerDirectorSell4,848$23.81$115,430.88View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/20/2015Henry E BlairDirectorSell50,000$27.05$1,352,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/8/2015David J MclachlanDirectorSell75,000$25.63$1,922,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/6/2015Andrew D AsheEVPSell2,400$15.50$37,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/5/2015Burt A AdelmanCMOSell9,375$15.66$146,812.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/5/2015George V MigauskyCFOSell5,000$15.86$79,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/5/2015Gustav ChristensenCEOSell6,250$15.86$99,125.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/26/2015Andrew D AsheEVPSell1,500$15.34$23,010.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/2/2015Burt A AdelmanCMOSell75,000$14.05$1,053,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/5/2014Thomas L KempnerDirectorSell14,764$13.79$203,595.56View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/21/2014Thomas L KempnerDirectorSell100,000$13.20$1,320,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/12/2014Thomas L KempnerDirectorSell12,400$11.00$136,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/26/2014Thomas L KempnerDirectorSell37,000$10.39$384,430.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/19/2014Thomas L KempnerDirectorSell113,755$9.67$1,100,010.85View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/7/2014Thomas L KempnerDirectorSell33,190$9.25$307,007.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/13/2014George V MigauskyCFOSell16,000$8.26$132,160.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/5/2014Henry BlairDirectorSell150,000$10.46$1,569,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/3/2014Andrew AsheEVPSell30,000$10.00$300,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/3/2014Burt AdelmanCMOSell55,000$9.68$532,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/26/2014Andrew AsheVPSell2,723$10.10$27,502.30View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/5/2013Thomas KempnerDirectorSell400,000$8.37$3,348,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/13/2013Andrew AsheVPSell32,500$4.30$139,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/16/2013Marc D KozinDirectorBuy22,971$2.46$56,508.66View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/25/2013George V MigauskyCFOSell4,275$3.28$14,022.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/25/2013Ivana MagovcevicCOOSell4,015$3.24$13,008.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Dyax Corp. (NASDAQ:DYAX)
DateHeadline
06/30/16 07:56 AMShire : Top-Line Results for Phase 2 Trial of SHP607
06/30/16 07:56 AMShire Announces Top-Line Results for Phase 2 Trial of SHP607 in Extremely Premature Infants
06/29/16 03:40 PMShire : Announces Positive Topline Results of SHP465 Efficacy and Safety Study in Adults With ADHD
06/28/16 08:35 AMEquity Research and Technical Review on Dyax Corp. (NASDAQ:DYAX) - Press Telegraph
06/23/16 08:45 PMKeryx Biopharmaceuticals Appoints Two New Board Members - GlobeNewswire (press release)
06/22/16 03:51 PMWhat Is Shire's Outlook for 2016? - Market Realist
06/21/16 08:25 AMKeryx Biopharmaceuticals Appoints Two New Board Members - Nasdaq
06/19/16 03:31 PMThis Weeks Broker Views For Dyax Corp. (DYAX) - Fiscal Standard
06/15/16 08:28 AMRecently Issued Stock Ratings For Dyax Corp. (DYAX) - Fiscal Standard
06/14/16 08:34 AMPfizer : Shire to License PF-00547659 from Pfizer, Adding to Established and Leading Gastrointestinal Portfolio
06/10/16 03:51 PMShire : Announces Completion of Decentralized Procedure in Europe for Immunoglobulin Treatment Cuvitru
06/07/16 03:51 PMFitch Downgrades Baxalta to 'BBB'; Withdraws Ratings - Business Wire (press release)
06/06/16 03:36 PMDYAX CORP. (NASDAQ:DYAX) Financial Condition Compared to S&P 500 - CML News
06/06/16 07:05 AMSigns of change: Shire finalizes acquisition of Baxalta
06/03/16 09:52 PMSigns of change: Shire finalizes acquisition of Baxalta - newtoncitizen
06/03/16 03:55 PMSigns of change: Shire finalizes acquisition of Baxalta - Rockdale Citizen
06/01/16 10:01 PMBroker Watchlist: Dyax Corp. (DYAX) - Share Trading News - Broker Watchlist: Dyax Corp. (DYAX)Share Trading News11/09/2015 – Dyax Corp. was downgraded to “market perform” by analysts at Leerink Swann. They now have a USD 37 price target on the stock. 11/05/2015 – Dyax Corp. had its “hold” rating reiterated by analysts at Needham & Company. 11/02/2015 – Dyax ...
05/30/16 09:38 PMTarget Check and Stock Performance Recap Dyax Corp. (NASDAQ:DYAX) - HNN - Target Check and Stock Performance Recap Dyax Corp. (NASDAQ:DYAX)HNNTracking stock performance from various views may help with share evaluation. Some investors might be more focused on short-term share action while others may prefer to view long-term performance. In recent session activity, Dyax Corp. (NASDAQ:DYAX) ...
05/30/16 09:38 PMTarget Check and Stock Performance Recap Dyax Corp. (NASDAQ:DYAX) - HNN - Target Check and Stock Performance Recap Dyax Corp. (NASDAQ:DYAX)HNNTracking stock performance from various views may help with share evaluation. Some investors might be more focused on short-term share action while others may prefer to view long-term performance. In recent session activity, Dyax Corp. (NASDAQ:DYAX) ...
05/30/16 09:38 PMStock Review and Earnings Check on Dyax Corp. (NASDAQ:DYAX) - HNN - Stock Review and Earnings Check on Dyax Corp. (NASDAQ:DYAX)HNNInvestors and analysts are typically super focused on company earnings numbers when they are reported. Company earnings are a good way to evaluate the company profitability. Currently, sell-side analysts are expecting Dyax Corp. (NASDAQ:DYAX) to ...
05/30/16 09:38 PMStock Review and Earnings Check on Dyax Corp. (NASDAQ:DYAX) - HNN - Stock Review and Earnings Check on Dyax Corp. (NASDAQ:DYAX)HNNInvestors and analysts are typically super focused on company earnings numbers when they are reported. Company earnings are a good way to evaluate the company profitability. Currently, sell-side analysts are expecting Dyax Corp. (NASDAQ:DYAX) to ...
05/27/16 07:23 PMHC Stocks to Path: Celgene Corporation (NASDAQ:CELG), Shire PLC (ADR) (NASDAQ:SHPG) - share market updates (press release) - HC Stocks to Path: Celgene Corporation (NASDAQ:CELG), Shire PLC (ADR) (NASDAQ:SHPG)share market updates (press release)Completed acquisition of Dyax Corp. (“Dyax”) and enrollment on track for SHP643 (formerly DX2930) Phase 3 studies for the treatment of Hereditary Angioedema (“HAE”). Patent upheld for LIALDA (mesalamine) delayed release tablets by U.S. District Court ...and more »
05/24/16 12:10 AMTarget Check and Stock Performance Recap Dyax Corp. (NASDAQ:DYAX) - Wall Street Hints and News - Target Check and Stock Performance Recap Dyax Corp. (NASDAQ:DYAX)Wall Street Hints and NewsTracking stock performance from various views may help with share evaluation. Some investors might be more focused on short-term share action while others may prefer to view long-term performance. In recent session activity, Dyax Corp. (NASDAQ:DYAX) ...and more »
05/24/16 12:10 AMEarnings Review and Stock Rundown for Dyax Corp. (NASDAQ:DYAX) - Wall Street Hints and News - Earnings Review and Stock Rundown for Dyax Corp. (NASDAQ:DYAX)Wall Street Hints and NewsInvestors and analysts will be paying close attention when the company posts earnings results. Earnings numbers can provide insight into a company's overall profitability. Covering equity analysts are expecting Dyax Corp. (NASDAQ:DYAX) to post ...and more »
05/18/16 07:00 PMLatest Analyst Ratings For Dyax Corp. (DYAX) - Share Trading News - Latest Analyst Ratings For Dyax Corp. (DYAX)Share Trading News11/09/2015 – Dyax Corp. was downgraded to “market perform” by analysts at Leerink Swann. They now have a USD 37 price target on the stock. 11/05/2015 – Dyax Corp. had its “hold” rating reiterated by analysts at Needham & Company. 11/02/2015 – Dyax ...
05/17/16 11:11 AMShare Recap and Earnings Focus on Dyax Corp. (NASDAQ:DYAX) - Wall Street Hints and News - Share Recap and Earnings Focus on Dyax Corp. (NASDAQ:DYAX)Wall Street Hints and NewsAnalysts and investors are usually very focused on company earnings numbers when they are released. Company earnings are a good way to evaluate the profitability of the company. Presently, covering analysts are anticipating Dyax Corp. (NASDAQ:DYAX) ...and more »
05/16/16 06:42 PMNext-generation Antibody Therapeutics Market will reach US$ 6761.1 Million by 2022 - Medgadget.com (blog) - Next-generation Antibody Therapeutics Market will reach US$ 6761.1 Million by 2022Medgadget.com (blog)Roche, Seattle Genetics, Takeda, Dyax Corp., and Immunogen are some of the leading players in the global market of next-generation antibody therapeutics. Some of the other major players in next-generation antibody therapeutics market are Amgen, Inc., ...
05/11/16 07:43 PMConsensus Rating Review for Dyax Corp. (NASDAQ:DYAX) - B.O.D.Y Confidential - Consensus Rating Review for Dyax Corp. (NASDAQ:DYAX)B.O.D.Y ConfidentialEquity research analysts currently have a consensus rating of N/A on shares of Dyax Corp. (NASDAQ:DYAX). Sell-side analysts will typically rate a company's stock based on extensive research. These ratings usually translate into a Buy, Sell, or Hold ...and more »
05/11/16 12:38 AMGalena Biopharma Reports First Quarter 2016 Financial Results and Provides a Corporate Update - GlobeNewswire (press release) - Galena Biopharma Reports First Quarter 2016 Financial Results and Provides a Corporate UpdateGlobeNewswire (press release)Dr. Gray currently serves on the board of directors of several publicly traded biotechnology companies: Acadia Pharmaceuticals, TetraLogic, Inc., Juniper Pharmaceuticals, Senomyx, Inc. Previously, Dr. Gray also served on the boards of Dyax Corp., GTC ...
05/09/16 07:10 PMFinancial Services Market Daily: Berkshire Hathaway, American International Group, First Citizens BancShares Inc - Most recently, Campili served as the head of healthcare investment banking for Europe, Middle East, and Africa (EMEA), and holds the distinction of having worked on the industry’s largest deals, including the company’s purchase of Dyax Corp. and Shire ...
05/04/16 07:19 PMAverage Analyst Rating for Dyax Corp. (NASDAQ:DYAX) - B.O.D.Y Confidential - Average Analyst Rating for Dyax Corp. (NASDAQ:DYAX)B.O.D.Y ConfidentialWall Street analysts have provided an average broker recommendation of N/A on Dyax Corp. (NASDAQ:DYAX) shares. The rating is determined by using the average of all analyst recommendations taken into consideration by Zacks Research.and more »
05/03/16 07:15 PMMario Gabelli Comments on Dyax Corp - Dyax Corp. (NASDAQ:DYAX) is a Burlington, Massachusetts based biopharmaceutical company. The company is targeting hereditary angioedema (HAE), a rare, genetic inflammatory condition, via their pipeline drug DX-2930, an injectable treatment for the ...
04/28/16 08:52 PMDyax Corp. (DYAX) Updated Broker Price Targets - Share Trading News - Dyax Corp. (DYAX) Updated Broker Price TargetsShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Dyax Corp. (DYAX). The latest reports which are currently in issue on Thursday 28th of April state 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 analysts ...and more »
04/27/16 02:30 AMDyax Corp. (NASDAQ:DYAX) Share Rating Recap - B.O.D.Y Confidential - Dyax Corp. (NASDAQ:DYAX) Share Rating RecapB.O.D.Y ConfidentialShares of Dyax Corp. (NASDAQ:DYAX) are tracked by analysts as well as crowd investors. Research from Beta Systems keeps track of crowd sourced sentiment and provides consensus stock ratings. The rating information comes mainly from financial ...and more »
04/21/16 08:59 PMDyax Corp. (NASDAQ:DYAX) Share Rating Recap - The Post - Dyax Corp. (NASDAQ:DYAX) Share Rating RecapThe PostShares of Dyax Corp. (NASDAQ:DYAX) are tracked by analysts as well as crowd investors. Research from Beta Systems keeps track of crowd sourced sentiment and provides consensus stock ratings. The rating information comes mainly from financial ...and more »
04/20/16 08:30 PMBroker Roundup For Dyax Corp. (DYAX) - Share Trading News - Broker Roundup For Dyax Corp. (DYAX)Share Trading News11/09/2015 – Dyax Corp. was downgraded to “market perform” by analysts at Leerink Swann. They now have a USD 37 price target on the stock. 11/05/2015 – Dyax Corp. had its “hold” rating reiterated by analysts at Needham & Company. 11/02/2015 – Dyax ...
04/15/16 08:46 PMDyax Corp. (NASDAQ:DYAX) Analyst Recommendation Outlook - Clinton Financial - Dyax Corp. (NASDAQ:DYAX) Analyst Recommendation OutlookClinton FinancialCovering analysts usually give Buy, Sell and Hold recommendations along with guidance and company earnings estimates. There are N/A analysts providing ratings for Dyax Corp. (NASDAQ:DYAX). N/A have given the stock a “Strong Buy”, N/A rate it a “Buy”, ...and more »
04/15/16 08:46 PMDyax Corp. (DYAX) Latest Broker Coverage - Risers & Fallers - Dyax Corp. (DYAX) Latest Broker CoverageRisers & FallersA number of investment brokers have recently updated their price targets on shares of Dyax Corp. (DYAX). According to the latest broker reports outstanding on Friday 15th of April, 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 analysts ...Dyax Corp. (NASDAQ:DYAX): Quick Look at EarningsNews Tribuneall 2 news articles »
04/13/16 08:02 PMView on Ratings Dyax Corp. (NASDAQ:DYAX) - Business Standard Tribune - View on Ratings Dyax Corp. (NASDAQ:DYAX)Business Standard TribuneUsing a scale from 1 to 5, Dyax Corp. (NASDAQ:DYAX) has a rating of N/A on the stock. A score of 1 or 2 indicates a Buy rating, and a score of 4 or 5 indicates a Sell rating. A 3 would indicate a Hold. This consensus number is made up of covering ...and more »
04/12/16 08:47 PMEarnings Watch on Dyax Corp. (NASDAQ:DYAX) - RiversideGazette.com - Earnings Watch on Dyax Corp. (NASDAQ:DYAX)RiversideGazette.comDyax Corp. (NASDAQ:DYAX) has a consensus earnings per share estimate for the current quarter of $N/A based on compiled analyst projections. The company is next expected to release earnings on or around N/A for the period ending N/A. For the same ...and more »
04/08/16 09:39 PMIs Dyax Corp. (NASDAQ:DYAX) a Consensus Buy? - Clinton Financial - Is Dyax Corp. (NASDAQ:DYAX) a Consensus Buy?Clinton FinancialEquity research firms covering public U.S companies have a workforce of analysts dedicating their time covering the most popular stocks. Their reports are delivered to institutional investors in order to help make investment decisions. The information ...and more »
04/07/16 02:19 AMDYAX CORP. (NASDAQ:DYAX) rating of Downgrade confirmed by Leerink Swann - Hints News Network - DYAX CORP. (NASDAQ:DYAX) rating of Downgrade confirmed by Leerink SwannHints News NetworkDYAX CORP. (NASDAQ:DYAX) opened at $38.41 on Friday. The company's 50-day moving average is $37.73 and it's 200-day moving average is $29.05. The business has a mkt cap of $ and a price-to-earnings ratio of . DYAX CORP. has a annual low of ...
04/06/16 09:03 PMAnalyst Ratings Check Dyax Corp. (NASDAQ:DYAX) - Business Standard Tribune - Analyst Ratings Check Dyax Corp. (NASDAQ:DYAX)Business Standard TribuneCovering sell-side analysts have an average rating of N/A on shares of Dyax Corp. (NASDAQ:DYAX). This Zacks Research number is compiled from analysts that they have taken into consideration. This consensus rating lands on a 1 to 5 scale. A 1 or 2 ...and more »
04/04/16 08:45 PMDyax Corp. (NASDAQ:DYAX) Assigned Rating Of N/A - Stocks Daily - Dyax Corp. (NASDAQ:DYAX) Assigned Rating Of N/AStocks DailySell-side analysts hold a positive view on Dyax Corp. (NASDAQ:DYAX) stock. Based on the poll results updated by the Zacks Research as of N/A, the company's stock has been given N/A rating. This score represents the rating on a scale of 1 to 5, where 1 ...and more »
04/01/16 07:45 PMBaker Bros Advisors Lp Increased Dyax Corp. (NASDAQ:DYAX) by $27.70 Million as Shares Rose - Business Standard Tribune - Baker Bros Advisors Lp Increased Dyax Corp. (NASDAQ:DYAX) by $27.70 Million as Shares RoseBusiness Standard TribuneJulian Baker increased its stake in Dyax Corp. (NASDAQ:DYAX) by 9.9% based on its latest Q4 2015 regulatory filing with the SEC. Baker Bros Advisors Lp bought 748,537 shares as the company's stock rose 97.79% with the market. The hedge fund run by ...
04/01/16 07:45 PMShould Investors Buy Dyax Corp. (NASDAQ:DYAX)? - Clinton Financial - Should Investors Buy Dyax Corp. (NASDAQ:DYAX)?Clinton FinancialThey issue Buy, Sell and Hold recommendations as well as earnings estimates and guidance. Out of the N/A analysts covering shares of Dyax Corp. (NASDAQ:DYAX), N/A rate it a “Strong Buy”, N/A rate it a “Buy”, N/A are advising to Hold the shares and N/A ...and more »
01/26/16 12:19 PMHere Are The Most Notable Insider Transactions Hitting The Market -
01/22/16 03:50 PMDYAX CORP Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to S -
01/22/16 08:16 AMShire Completes Acquisition of Dyax - [PR Newswire] - Shire plc (LSE: SHP, NASDAQ: SHPG) today announced that it has completed its acquisition of Dyax Corp. (DYAX) in an all-cash transaction valued at approximately $5.9 billion, comprised of $37.30 in cash per Dyax share. Dyax shareholders may receive additional value through a non-tradable contingent value right (CVR) that will pay $4.00 in cash per Dyax share upon approval of DX-2930 for HAE, representing a potential additional $646 million in aggregate contingent consideration. "We are excited to complete the acquisition of Dyax and look forward to working alongside their very talented and committed team to address significant unmet patient need around the world.
12/11/15 07:09 AMDyax Corp. Sets January 21, 2016 As Date of Special Stockholder Meeting To Vote On Its Proposed Acquisition By Shire plc - [at noodls] - --(BUSINESS WIRE)-- (NASDAQ:DYAX) ('Dyax') today announced it has set a date for a special meeting of its stockholders to consider and vote on the previously announced proposed acquisition of by Shire ...
About Dyax Corp.

Dyax Corp. logoDyax Corp is a biopharmaceutical company. The Company is focused on Hereditary Angioedema (HAE) and other Plasma-Kallikrein-Mediated (PKM) Disorders, and licensing and funded research portfolio. The Company develops and commercializes treatments for hereditary angioedema. The Company discovered and developed KALBITOR, a plasma kallikrein inhibitor, and is selling it in the United States for the treatment of acute attacks of HAE. Additionally, it discovered and is developing DX-2930, a human monoclonal antibody inhibitor of plasma kallikrein. It also developed a biomarker assay that detects the activation of plasma kallikrein in patient blood. The Company has a portfolio of product candidates being developed by licensees using its phage display technology. This portfolio includes one approved product, CYRAMZA (ramucirumab), which is marketed by Eli Lilly and Company (Lilly), and multiple product candidates in various stages of clinical development.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: DYAX
  • CUSIP: 26746E10
Key Metrics:
  • Previous Close: $38.41
  • 50 Day Moving Average: $37.73
  • 200 Day Moving Average: $29.05
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $N/A
  • Current Quarter EPS Consensus Estimate: $-0.26 EPS
Additional Links:
Dyax Corp. (NASDAQ:DYAX) Chart for Friday, July, 1, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha